HebatAlla Fathi Mohamed Mousa1,2, Nesrin Kamal Abd-El-Fatah3, Olfat Abdel-Hamid Darwish3, Shehata Farag Shehata4, Shady Hassan Fadel5. 1. Department of Nutrition, High Institution of Public Health, Alexandria University, Alexandria, Egypt. drheba_fmoussa@yahoo.com. 2. , Buraidah, Al-Qassim, Saudi Arabia. drheba_fmoussa@yahoo.com. 3. Department of Nutrition, High Institution of Public Health, Alexandria University, Alexandria, Egypt. 4. Department of Biostatistics, High Institute of Public Health, Alexandria University, Alexandria, Egypt. 5. Department of Pediatric oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
PURPOSE: Seeds of Nigella sativa (NS) are used to combat various disease conditions through their antibacterial effects. To evaluate the seeds' potential, we studied their effect on the prevention of febrile neutropenia (FN) in children with brain tumors. METHODS: A randomized pretest-post-test control group study including 80 children (2-18 years) with brain tumors undergoing chemotherapy were equally allocated into two groups. Intervention group received 5 g of NS seeds daily throughout treatment while controls received nothing. CBC with differentials, incidence of FN, and LOS were noted on each follow-up. RESULTS: The majority of children 38/40 (95%), of the intervention group, took the seeds for 3-9 consecutive months. Eight out of 372 (2.2%) FN episodes were experienced by children of intervention group compared to controls 63/327 (19.3%) (p = 0.001) and a shorter LOS (median = 2.5 days) vs 5 days in the control group (p = 0.006). Children in both groups belonged to almost same geographical area with similar socio-economic background. Weights of children were almost equal at diagnosis. CONCLUSION: NS seeds showed a decrease in incidence of FN in children with brain tumors with shortening of subsequent LOS which may improve their outcome and thereby quality of life. Larger scale studies are needed to further evaluate the seeds' potential.
RCT Entities:
PURPOSE: Seeds of Nigella sativa (NS) are used to combat various disease conditions through their antibacterial effects. To evaluate the seeds' potential, we studied their effect on the prevention of febrile neutropenia (FN) in children with brain tumors. METHODS: A randomized pretest-post-test control group study including 80 children (2-18 years) with brain tumors undergoing chemotherapy were equally allocated into two groups. Intervention group received 5 g of NS seeds daily throughout treatment while controls received nothing. CBC with differentials, incidence of FN, and LOS were noted on each follow-up. RESULTS: The majority of children 38/40 (95%), of the intervention group, took the seeds for 3-9 consecutive months. Eight out of 372 (2.2%) FN episodes were experienced by children of intervention group compared to controls 63/327 (19.3%) (p = 0.001) and a shorter LOS (median = 2.5 days) vs 5 days in the control group (p = 0.006). Children in both groups belonged to almost same geographical area with similar socio-economic background. Weights of children were almost equal at diagnosis. CONCLUSION:NS seeds showed a decrease in incidence of FN in children with brain tumors with shortening of subsequent LOS which may improve their outcome and thereby quality of life. Larger scale studies are needed to further evaluate the seeds' potential.
Authors: André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300
Authors: Daniel A de Luis; Olatz Izaola; Luis Cuellar; M Concepcion Terroba; Gloria Cabezas; S Rojo; Rocio Aller; M Gonzalez Sagrado Journal: Ann Nutr Metab Date: 2006-06-30 Impact factor: 3.374
Authors: Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2015-01 Impact factor: 12.300
Authors: P Riikonen; U M Saarinen; A Mäkipernaa; L Hovi; A Komulainen; J Pihkala; H Jalanko Journal: Pediatr Infect Dis J Date: 1994-03 Impact factor: 2.129